Skip to main content
SpringerLink
Log in

Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases

  • Clinical study - Patient study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Not all Glioblastoma multiforme (GBM, grade IV WHO) manifest the same clinical course. Different prognostic classes may arise from different morphologic and genetic profiles. The observation of oligodendroglial foci within GBM samples and their correlation with genetic alterations may predict a better prognosis. 450 patients affected by histologically proven supratentorial cerebral GBM were treated at our institutions from January 2000 to December 2006: all patients received at least subtotal surgical removal, followed by the same standard radio-chemotherapy adjuvant treatment. In a subgroup of 36 patients (8.0%) an oligodendroglial component was observed. Molecular assessment of these cases was performed and LOH for 1p, 19q and 10q, EGFR amplification and TP53 gene expression was determined. Median age of this subgroup was 52.1 years (range: 29–78 years) vs 62.4 years in the entire GBM population. Chromosome analysis resulted as follows: LOH 1p and/or 19q in 27 cases (75.0%), LOH of 10q in 21 cases (58.1%), EGFR amplification in 14 cases (39%) and TP53 mutation in eight patients (22.2%). OS was of 20.9 months while it was 13.6 months in the entire GBM population. Progression free survival (PFS) was 10.3 months and 7.6 months the entire group. Two-year survival was of 55%. The presence of an oligodendroglial component in GBM appears to be an important prognostic factor to which better prognosis can be related. LOH 1p and 19q was significantly associated with GBM with oligodendroglial component.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) World Health Organization classification of tumours of the central nervous system. IARC Press, Lyon, pp 33–49

    Google Scholar 

  2. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, Ohgaki H (2006) Correlation among pathology, genotype and patient outcome in glioblastoma. J Neuropathol Exp Neurol 65(9):846–854. doi:10.1097/01.jnen.0000235118.75182.94

    Article  PubMed  CAS  Google Scholar 

  3. Kraus JA, Glesmann N, Beck M et al (2000) Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long- term survivors of glioblastoma multiforme. J Neurooncol 48:89–94. doi:10.1023/A:1006402614838

    Article  PubMed  CAS  Google Scholar 

  4. Houillier C, Lejeune J, Benouaich-Amiel A et al (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218–2223. doi:10.1002/cncr.21819

    Article  PubMed  CAS  Google Scholar 

  5. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543

    PubMed  CAS  Google Scholar 

  6. Okamoto Y, Di Patre PL, Burkhard C et al (2004) Population- based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56. doi:10.1007/s00401-004-0861-z

    Article  PubMed  Google Scholar 

  7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331

    Article  PubMed  CAS  Google Scholar 

  8. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 101:311–320

    PubMed  CAS  Google Scholar 

  9. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S (2004) Histological indications of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 44:555–560. doi:10.1111/j.1365-2559.2004.01887.x

    Article  PubMed  CAS  Google Scholar 

  10. Decaestecker C, Camby I, Gordower L et al (1998) Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy. J Neuropathol Exp Neurol 57:791–802. doi:10.1097/00005072-199808000-00008

    Article  PubMed  CAS  Google Scholar 

  11. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K (2001) Glioblastomas with oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871

    PubMed  CAS  Google Scholar 

  12. Ghimenti C, Fiano V, Chiadò-Piat L, Chiò A, Cavalla P, Schiffer D (2003) Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J Neurooncol 61:95–102. doi:10.1023/A:1022127302008

    Article  PubMed  Google Scholar 

  13. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Hoang-Xuan K, Thillet J, Delattre JY, Sanson M (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107:1891–1897. doi:10.1002/cncr.22211

    Article  PubMed  CAS  Google Scholar 

  14. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4 and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196–201

    PubMed  CAS  Google Scholar 

  15. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidemial growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822–831. doi:10.1097/00005072-199607000-00007

    Article  PubMed  CAS  Google Scholar 

  16. von Deimling A, Nagel J, Bender B et al (1994) Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57:676–680. doi:10.1002/ijc.2910570511

    Article  Google Scholar 

  17. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN (2003) Gene expression-based classification of malignant gliomas correlates with better survival than histological classification. Cancer Res 63:1602–1607

    PubMed  CAS  Google Scholar 

  18. Idbaih A, Marie Y, Pierron G et al (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483–487. doi:10.1002/ana.20607

    Article  PubMed  CAS  Google Scholar 

  19. Kraus JA, Wegendorfer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, Diete S, Dietzmann K, Müller B, Heuser K, Reifenberger G, Schlegel U (2000) Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 247:455–460. doi:10.1007/s004150070175

    Article  PubMed  CAS  Google Scholar 

  20. Caincross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.1093/jnci/90.19.1473

    Article  Google Scholar 

  21. Ino Y, Zlatescu M, Sasaki H et al (2000) Long survival and therapeutic responses in patients with histologically disparate high grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983–990

    Article  PubMed  CAS  Google Scholar 

  22. Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Koelbl O, Flentje M (2006) Glioblastoma multiforme with oligodendroglial component (GMBO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and tenipside (VM 26). BMC Cancer 6:247. doi:10.1186/1471-2407-6-247

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroscience-Neurosurgery Department, “Sapienza” University, Via Cardinal Agliardi, 15, 00165, Rome, Italy

    Maurizio Salvati, Anna I. Formichella, Alessandro D’Elia, Cristian Brogna, Alessandro Frati, Felice Giangaspero, Roberto Delfini & Antonio Santoro

  2. Neurosurgery Department, INM Neuromed IRCCS, Pozzilli (IS), Italy

    Maurizio Salvati & Felice Giangaspero

Authors
  1. Maurizio Salvati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna I. Formichella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro D’Elia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristian Brogna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro Frati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Felice Giangaspero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Delfini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Salvati.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salvati, M., Formichella, A.I., D’Elia, A. et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94, 129–134 (2009). https://doi.org/10.1007/s11060-009-9815-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9815-6

Keywords

Search

Navigation